Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 7/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394934 | 0.82 | KDR (0.44) | RPS6KB1NPC1VNN1KCNH3KDR | |
| SCHEMBL6314646 | 0.74 | AURKA (0.54) | AURKANPC1HDAC6KCNH3TERT | |
| SCHEMBL6395410 | 0.74 | AURKA (0.54) | AURKANPC1HDAC6KCNH3TERT | |
| SCHEMBL8908495 | 0.69 | STK17A (0.49) | VNN1KCNH3KDM4E | |
| SCHEMBL6393984 | 0.68 | KDR (0.56) | ULK1ULK2AURKANPC1TERT | |
| SCHEMBL1392072 | 0.68 | IDH2 (0.62) | KCNH3 | |
| SCHEMBL8908486 | 0.67 | STK17A (0.50) | VNN1KCNH3KDM4E | |
| SCHEMBL5758552 | 0.67 | NPC1 (0.60) | ULK1ULK2NPC1GRM4TERT | |
| SCHEMBL6395412 | 0.66 | TERT (0.48) | AURKANPC1TERTKDR | |
| SCHEMBL6406526 | 0.65 | KDR (0.52) | NPC1KCNH3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | claimed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | TIE1, KDR, FLT1 | RPS6KB1 2597/4885ULK1 2280/4885ULK2 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.